Wolff-Parkinson-White Syndrome

• Accessory Pathway Development and Anatomy: Accessory pathways represent remnants of myocardial tissue that failed to regress during embryonic development of the fibrous annulus of the heart. These pathways are composed of ventricular myocardium or specialized conducting tissue that directly bridges the atrial and ventricular myocardium, bypassing the insulating fibrofatty tissue that normally isolates these chambers. The most common location is the left free wall (50-60%), followed by the posteroseptal region (25%), right free wall (15%), and anteroseptal region (5-10%). Unlike the AV node, which exhibits decremental conduction properties and a physiologic refractory period of 250-350 milliseconds, accessory pathways typically possess rapid conduction properties with shorter refractory periods (140-250 ms), allowing rapid transmission of impulses and enabling the electrocardiographic hallmark of delta wave (slurred upstroke of the QRS complex) during sinus rhythm.

• Delta Wave Generation and Pre-excitation: During sinus rhythm in WPW, atrial depolarization simultaneously activates both the normal AV nodal pathway and the accessory pathway. Because the accessory pathway conducts faster (velocity 0.5-1.5 m/sec vs. AV node velocity of 0.02-0.05 m/sec), the ventricle is partially depolarized via the accessory pathway before completion of AV nodal conduction, resulting in a shortened PR interval (<120 ms) and early ventricular activation. The portion of the ventricle depolarized by the accessory pathway produces the pathognomonic delta wave (initial slurred portion of QRS), while the remainder of the ventricle is depolarized normally via the AV node-His-Purkinje system. The degree of pre-excitation and delta wave prominence depends on the conduction velocity of the accessory pathway relative to the AV node and the anatomic location of the pathway; pathways with rapid conduction produce marked pre-excitation, while slowly conducting pathways may produce minimal delta waves.

• Mechanism of Atrioventricular Reentrant Tachycardia (AVNRT): The accessory pathway serves as a substrate for reentrant arrhythmias through a dual-pathway circuit. In the most common orthodromic AVNRT (90% of cases), sinus impulses conduct anterograde (downward) through the AV node with its slower conduction and longer refractory period, then retrogradely (upward) through the rapidly conducting accessory pathway back to the atrium, completing a circuit. This produces a regular, rapid tachycardia typically with rates of 140-250 bpm. The reentry circuit depends on unidirectional block—the impulse can only conduct in one direction through each pathway—which allows the impulse to continually cycle. Antidromic AVNRT (10% of cases) occurs when conduction is anterograde through the accessory pathway and retrograde through the AV node, producing a wide-complex tachycardia. The initiating mechanism usually involves a critically timed atrial or ventricular premature beat that encounters one pathway in its refractory period while the other pathway has recovered excitability, establishing the necessary conduction pattern.

• Enhanced Conduction During Atrial Fibrillation: A critical and potentially life-threatening pathophysiologic feature involves the behavior of accessory pathways during atrial fibrillation (AFib). Unlike the AV node, which has decremental conduction properties and a long refractory period that protect the ventricles from rapid atrial rates, accessory pathways conduct rapidly without decrement and may have substantially shorter refractory periods. During AFib in WPW patients, atrial impulses can rapidly traverse the accessory pathway with minimal delay, allowing rapid ventricular rates (frequently >250 bpm). This rapid ventricular response can precipitate ventricular fibrillation, particularly if R-on-T phenomena occur. This represents the primary life-threatening manifestation of WPW and mandates careful evaluation of the accessory pathway's conduction properties and refractory period.

• Electrophysiologic Properties of Accessory Pathways: Individual accessory pathways exhibit variable electrophysiologic characteristics that determine clinical risk. The effective refractory period (ERP) of the accessory pathway—the longest interval at which an impulse cannot conduct—is the most critical determinant of risk during AFib; pathways with ERPs <250 ms are considered high-risk, as they permit more rapid ventricular conduction during AFib. Concealed accessory pathways, which conduct only retrogradely (from ventricle to atrium) and therefore do not produce pre-excitation on baseline ECG, cannot conduct atrial impulses to the ventricles during AFib and therefore do not pose the same risk of rapid ventricular rates. Pathway location also influences conduction properties: right free wall pathways tend to have shorter ERPs and greater risk, while left-sided pathways typically conduct more slowly.

• Idiopathic Accessory Pathways: The vast majority of WPW cases (approximately 70%) occur without associated cardiac or systemic disease, representing developmental anomalies of embryologic tissue that failed to fully regress during atrial-ventricular insulation development. These pathways are sporadic and do not follow clear Mendelian inheritance patterns, though familial clustering has been reported in approximately 3-5% of cases, suggesting possible genetic predisposition in some families.

• Associated Cardiac Conditions: Several congenital and structural cardiac conditions demonstrate increased prevalence of accessory pathways. Ebstein's anomaly shows the strongest association, with accessory pathways identified in approximately 10-25% of Ebstein patients, most commonly located in the posteroseptal region; the right-sided location of Ebstein's anomaly is thought to provide anatomic substrate for accessory pathway formation. Hypertrophic cardiomyopathy has increased prevalence of accessory pathways compared to general population. Other associated conditions include atrial septal defects, ventricular septal defects, tetralogy of Fallot, and L-transposition of the great arteries (corrected TGA).

• Syndromic Associations: Several inherited syndromes feature accessory pathways as a component of their phenotype. Pompe disease (glycogen storage disease type II) can present with WPW. Danon disease (lysosomal-associated membrane protein 2 deficiency) frequently presents with pre-excitation and accessory pathways alongside skeletal myopathy and cardiomyopathy. These syndromic presentations underscore the importance of considering systemic disease in pediatric patients presenting with WPW, particularly if extracardiac manifestations are present.

• Palpitations: The most common presenting symptom, occurring in approximately 50-70% of symptomatic WPW patients. Palpitations typically represent awareness of atrioventricular reentrant tachycardia and manifest as regular, rapid palpitations that begin and end abruptly—the sudden initiation reflects the reentrant mechanism's dependence on appropriately timed premature beats initiating the circuit. Patients characteristically report heart rates of 140-250 bpm and may describe the sensation as pounding in the chest or neck. The abrupt onset distinguishes reentrant tachycardias from sinus tachycardia, which typically accelerates gradually.

• Syncope and Presyncope: Occurring in 10-15% of symptomatic patients, syncope during AVNRT reflects rapid ventricular rates (>200 bpm) that cause inadequate ventricular filling and impaired cerebral perfusion. Pre-syncope or lightheadedness during episodes indicates borderline hemodynamic compromise. Syncope is a particularly concerning symptom suggesting either very rapid reentrant rates or—more ominously—atrial fibrillation with rapid conduction over the accessory pathway. Any WPW patient presenting with syncope requires urgent evaluation and often invasive electrophysiology testing to assess accessory pathway properties and establish risk.

• Chest Discomfort and Dyspnea: Experienced by some patients during sustained tachycardia, reflecting demand ischemia from rapid rates in the setting of normal coronary arteries. Dyspnea may occur with prolonged tachycardic episodes due to impaired cardiac output and pulmonary venous congestion. These symptoms are typically rate-dependent and resolve promptly upon termination of the arrhythmia.

• Asymptomatic Pre-excitation: A substantial proportion of patients (30-50% of those with baseline ECG evidence of WPW) remain completely asymptomatic and never develop arrhythmias during life. These patients are identified incidentally on screening ECG, presenting a clinical management dilemma regarding need for further testing and treatment.

• Physical Examination Findings: During sinus rhythm, physical examination is typically normal. During acute AVNRT, examination may reveal rapid, regular pulse at rates of 140-250 bpm; signs of hemodynamic compromise including hypotension, decreased mental status, or signs of pulmonary edema may develop with sustained rapid rates. Cannon A waves in the jugular venous pulse may be visible if atrial contraction occurs against a closed tricuspid valve. During atrial fibrillation with rapid conduction, examination reveals irregular, rapid pulse reflecting the chaotic atrial activity and variable accessory pathway/AV nodal conduction.

• Important Clinical Variant - Atrial Fibrillation with Rapid Conduction: A critical presentation occurs when atrial fibrillation with rapid conduction over the accessory pathway develops, producing ventricular rates that may exceed 300 bpm and carrying high risk of degenerating to ventricular fibrillation. Approximately 10-25% of symptomatic WPW patients experience AFib at some point, and this arrhythmia should be considered a medical emergency requiring urgent interventions.

• Baseline Electrocardiography: The hallmark diagnostic finding in WPW during sinus rhythm is the delta wave, a distinctive slurred upstroke at the beginning of the QRS complex caused by early ventricular depolarization via the accessory pathway. Supporting features include: (1) shortened PR interval (<120 ms, typically 50-90 ms), reflecting accelerated atrioventricular conduction; (2) wide QRS complex (≥120 ms), resulting from fusion of ventricular depolarization via both pathways and slower accessory pathway conduction compared to the specialized His-Purkinje system; and (3) secondary ST-T wave changes (ST depression and T wave inversion), which reflect abnormal repolarization in pre-excited areas. The direction and morphology of the delta wave and the resultant QRS axis depend on accessory pathway location—this principle forms the basis of anatomic localization of pathways using algorithms that examine delta wave polarity in precordial and limb leads. Right free wall pathways typically produce positive delta waves in lead aVL, while left free wall pathways produce negative delta waves in lead aVL; posteroseptal pathways show characteristic patterns in the inferior leads.

• Holter Monitor and Event Recording: For symptomatic patients with documentation of clinical events, 24-hour Holter monitoring or extended event monitoring may capture episodes of AVNRT or AFib during symptomatic spells, providing diagnostic confirmation. However, many WPW patients have infrequent arrhythmia episodes, making Holter monitoring insensitive despite high specificity when positive. Implantable loop recorders are increasingly used in patients with infrequent but significant symptoms.

• Echocardiography: Transthoracic echocardiography should be performed in all WPW patients to: (1) exclude structural cardiac disease, particularly Ebstein's anomaly, which is present in 10-25% of WPW patients and typically involves anterior leaflet displacement of the tricuspid valve with associated right ventricular dilation and apical trabeculation; (2) assess left ventricular ejection fraction and wall motion; and (3) evaluate for other congenital or acquired cardiac abnormalities. Echocardiography is normal in the majority of WPW patients but has crucial therapeutic implications when abnormalities are identified.

• Invasive Electrophysiology Study: Electrophysiology (EP) study represents the gold standard for definitive WPW diagnosis, localization, and risk stratification and is indicated for: (1) symptomatic patients to confirm diagnosis and evaluate arrhythmia mechanism; (2) risk stratification of accessory pathways; and (3) therapeutic intervention (catheter ablation). During EP study, programmed atrial stimulation is performed to induce arrhythmias and assess accessory pathway effective refractory period (ERP). The shortest pre-excited RR interval during induced atrial fibrillation is the most predictive indicator of risk during spontaneous AFib—values <250 ms identify high-risk pathways associated with rapid ventricular rates during AFib. Pathway location is precisely determined during EP study, and the retrograde conduction properties of the pathway are assessed. EP study also evaluates the AV nodal refractory period to understand the dual-pathway substrate for reentry.

• Diagnostic Criteria and Risk Stratification: WPW diagnosis requires baseline ECG evidence of pre-excitation (delta wave + short PR interval + wide QRS) OR clinical arrhythmias in the setting of baseline pre-excitation. For risk assessment of asymptomatic pre-excitation, current guidelines emphasize that true high-risk features include: (1) accessory pathway ERP <250 ms (assessed during EP study); (2) shortest pre-excited RR interval during AFib <250 ms; or (3) inducible AVNRT. Conversely, low-risk findings include slowly conducting pathways with ERPs >270 ms, inability to induce arrhythmias, or concealed pathways (those conducting only retrogradely).

• Differential Diagnosis Considerations:
• Lown-Ganong-Levine (LGL) syndrome: Features short PR interval with normal-width QRS (no delta wave), representing enhanced AV nodal conduction or an atrial-His bypass tract; does not carry WPW arrhythmia risk.
• Atrial fibrillation with rapid ventricular response in non-WPW patients: Differentiated by absence of delta wave on baseline ECG and normal PR interval.
• SVT from AV nodal reentrant tachycardia (AVNRT) without accessory pathways: More common than WPW-associated AVNRT in the general population; baseline ECG is normal without delta waves.
• Atrial flutter with 1:1 conduction: Can mimic WPW with rapid rates but presents with atrial flutter waves visible at slower rates.

• Asymptomatic Pre-excitation Without High-Risk Features: For patients with incidentally discovered pre-excitation who are completely asymptomatic and lack high-risk EP study features, current evidence supports a conservative approach without routine ablation. Risk of sudden cardiac death in asymptomatic WPW is approximately 0.4% (approximately 1 death per 500 asymptomatic patients over 10-25 years), which is substantially lower than previously estimated. These patients should receive counseling regarding symptoms prompting urgent evaluation and may safely participate in most competitive sports. Antiarrhythmic drugs are not routinely recommended for asymptomatic pre-excitation unless high-risk features are identified.

• Acute Termination of AVNRT: For symptomatic patients experiencing acute AVNRT, the goal is rapid termination of the reentrant circuit.
• Vagal maneuvers: Initial management includes Valsalva maneuver (straining against closed glottis) or carotid massage (performed cautiously, unilaterally for

Life-threatening arrhythmic complications (emergencies)

• Pre-excited atrial fibrillation: atrial impulses are funneled down a non-decremental bypass tract, producing an irregularly irregular, wide, bizarre, beat-to-beat-varying QRS tachycardia — the classic "FBI" (fast, broad, irregular) tracing. Rates may exceed 250-300 bpm. This is a true emergency: unstable patients get immediate synchronized cardioversion, and the 2015 ACC/AHA/HRS SVT guideline supports IV procainamide or ibutilide (agents that prolong accessory-pathway refractoriness) in the stable patient.
• Ventricular fibrillation and sudden cardiac death: degeneration of pre-excited AF when a rapid impulse lands on the vulnerable phase of repolarization (R-on-T). In a minority of patients this is the sentinel event, which is why syncope in a pre-excited patient mandates urgent evaluation.
• Iatrogenic acceleration from AV nodal blockade: adenosine, verapamil/diltiazem, beta blockers, and digoxin block the node, remove the competing wavefront, and shift all conduction to the accessory pathway; verapamil and digoxin may additionally shorten pathway refractoriness. The signal is abrupt QRS widening and rate acceleration after drug administration, followed by VF. These agents are contraindicated in pre-excited AF per ACC/AHA/HRS. Because adenosine itself can provoke atrial fibrillation, a defibrillator should be immediately available whenever it is used in pre-excitation.

Non-emergent complications

• Tachycardia-induced cardiomyopathy: incessant reentry (classically the slowly conducting concealed pathway of permanent junctional reciprocating tachycardia) causes progressive LV dilation and systolic dysfunction; suspect it when an "idiopathic" cardiomyopathy coexists with near-continuous tachycardia. It typically reverses after ablation.
• Pseudo-infarct pattern: negative delta waves mimic pathologic Q waves and secondary ST-T changes mimic ischemia, leading to misdiagnosis of prior or acute MI.
• Ablation-related injury: AV block requiring permanent pacing (highest with septal/para-Hisian pathways), tamponade, vascular access injury, and recurrence of pathway conduction in a small minority requiring repeat procedure.

• The ECG triad: short PR (<120 ms) + delta wave + wide QRS with secondary ST-T changes. Pre-excitation alone is a pattern; "syndrome" requires symptomatic arrhythmia.
• The delta wave vanishes during orthodromic tachycardia: in orthodromic AVRT the ventricle is depolarized only through the His-Purkinje system, so the tachycardia is narrow-complex and regular and looks like ordinary SVT. Always ask for the baseline/post-conversion ECG — that is where the diagnosis lives.
• Single best next step depends on regularity: a regular narrow-complex tachycardia gets vagal maneuvers then adenosine 6 mg IV rapid push (repeat 12 mg). An irregular, wide, polymorphic tachycardia is pre-excited atrial fibrillation — cardiovert if unstable, use procainamide or ibutilide if stable.
• The classic distractor: giving adenosine, verapamil, diltiazem, a beta blocker, or digoxin to a patient in pre-excited AF. Per the 2015 ACC/AHA/HRS SVT guideline these are contraindicated because blocking the node drives conduction down the bypass tract toward VF. The mnemonic ABCD (Adenosine, Beta blockers, Calcium channel blockers, Digoxin) flags what to avoid.
• The association examiners test: Ebstein anomaly — apically displaced, atrialized tricuspid valve, associated with right-sided/posteroseptal and often multiple accessory pathways; linked on stems to first-trimester lithium exposure. Also remember Danon and Pompe disease in children with pre-excitation.
• Definitive therapy is catheter ablation of the accessory pathway, recommended by ACC/AHA/HRS as first-line for symptomatic patients and highly effective.
• Low-risk markers: intermittent pre-excitation, or abrupt loss of the delta wave during exercise testing — both indicate a long pathway refractory period and reassure against rapid conduction in AF.
• Do not conflate AVRT with AVNRT: AVNRT uses dual pathways within the AV node and has a normal baseline ECG; only an accessory pathway produces a delta wave.